Rutland Herald

Peptilogics Begins Pivotal Trial of First-Ever Drug Designed to Cure Medical Device-Related Infections

Peptilogics' PLG0206 is a first-in-class anti-biofilm drug candidate being studied in patients with prosthetic joint infection (PJI), the first of multiple potential medical device-related infections ...
The Manila Times

Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for ...

New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson’s diseaseFirst ...
ascopubs.org

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study Participants had ...

Pfizer reports positive data from a Phase 2 study for the atopic dermatitis antibody

Pfizer ( PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results.